Entellus Medical (ENTL) Misses Q2 EPS by 3c

Entellus Medical (NASDAQ: ENTL) reported Q2 EPS of ($0.37), $0.03 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $22.1 million versus the consensus estimate of $21.49 million.

Entellus expects full year 2017 revenue, inclusive of anticipated Spirox revenue from July 13 through year end, to be in a range of $91.5 million to $94.5 million, representing growth of 22% to 26% over 2016 revenue. Excluding the impact of purchase accounting, non-GAAP adjusted combined gross margin is expected to be in a range of 72% to 74% for the full year 2017. Full year 2017 non-GAAP adjusted EBITDA, inclusive of Spirox operations and as described later in this release, is expected to be in a range of negative $22.0 million to negative $26.0 million.

For earnings history and earnings-related data on Entellus Medical (ENTL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15